Archeus Technologies in Madison and WARF are launching a clinical trial this year for a targeting molecule used in treating prostate cancer.
The organizations yesterday announced the plans to further develop ART-101, a receptor-based targeting molecule developed at UW-Madison’s Advanced Radiotheranostics lab. It’s designed to deliver radioactive isotopes within the body as part of a targeted trea...
